Role of SASH3 in normal and malignant T cells
Funded at University of Chicago · NIH-11449440 · Data updated 2026-11-12
A study exploring how a protein called SASH3 helps T cells grow and survive, with a focus on relapsed T-ALL, to identify potential new ways to treat this deadly leukemia.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | August 6, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $450,685 |
| NIH project number | 1R37CA309658-01A1 |
| Project ID | NIH-11449440 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with relapsed T-ALL or other T-cell leukemias may be eligible for future trials or related studies researching SASH3-based therapies.
✕Less likely to help
Patients without T-cell leukemias or without relapsed disease may not directly benefit from this research.
What this research studies
This project looks at how SASH3 supports signaling in normal and cancerous T cells and whether blocking this pathway can trigger cancer cell death. The researchers will map proteins and phosphorylation sites related to SASH3, compare cancerous T cells to normal ones, and test what happens when SASH3 function is reduced or altered. The goal is to uncover vulnerabilities in T-ALL that could be targeted by new therapies to improve outcomes for patients with relapsed disease.
Why it matters
Potential benefit: If successful, the work could reveal new targets for therapy in relapsed T-ALL and guide the development of treatments that disrupt SASH3-related signaling to kill cancer cells.
How similar studies have gone: Preliminary data in T-cell cancers suggest targeting signaling adaptors can affect survival, supporting the potential of this approach.
Where this research is happening
-
University of Chicago
Chicago, United States Active
Researchers
- Principal investigator: Saygin, Caner — University of Chicago
- Study coordinator: Saygin, Caner
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.